Full-Time
Manager – Document Control and Training
Jade Biosciences
51-200 employees
Develops, licenses, and commercializes biologic therapies
Compensation Overview
$130k - $140k/yr
Boston, MA, USA + 2 more
More locations: Seattle, WA, USA | San Francisco, CA, USA
Remote
Periodic travel to team and company events required.
Bachelor's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Jade Biosciences
See people who can refer or advise you
- Bachelors degree and 5-8+ years of pharmaceutical/biotech R&D experience, including 3-5+ years of experience in Document Control
- Experience administering training and documentation in Veeva Basics is a must
- Strong administrative and organizational skills
- Proficient in file and electronic data management systems
- Excellent technical writing skills
- Knowledge of records management principles and practices
- Familiarity with document management software
- Proficiency in using SharePoint and Microsoft Office applications required (MS Outlook, MS Word, MS Excel, MS PowerPoint)
- Support the full document lifecycle including creation, review, approval, distribution, revision, archival, and obsolescence.
- Ensure controlled documentation complies with all required internal requirements including formatting of controlled documents.
- Route documents for signature and ensure requirements are met.
- Establish and maintain training matrices/curricula aligned to job functions.
- Create and manage training and document management metrices.
- Drive continuous improvement in training effectiveness (including onboarding, recurring training, and inspection preparedness) and document management processes.
- Ensure accurate training records and audit-ready traceability.
- Represent Document Control and Training at data reviews, including Management Review, highlighting trends, risks and improvement opportunities as requested.
- Ensure that documents are properly organized, stored, and accessible to authorized personnel.
- Maintain accurate logs and archives.
- Oversee document version control and support report generation.
- Support process and/or system related changes to the document management and training systems.
- Collaborate and follow up with cross-functional teams to gather and review documentation requirements, provide system/process specific support and gather and review areas of improvement.
Jade Biosciences develops and commercializes biologic therapies. It builds a pipeline of potentially best-in-class biologics and advances them from discovery to market, using research, development, and strategic collaborations. Its products are engineered biologics—lab-made medicines designed to interact with the body's systems to treat diseases for which there are unmet medical needs. The company differentiates itself through its backing from Paragon Therapeutics and Fairmount, and by leveraging Paragon’s discovery-stage assets to pursue a focused pipeline with potential partnerships and licensing opportunities. Its goal is to bring effective biologic treatments to patients, generate revenue from product sales, licensing deals, and partnerships, and protect patient data while working with compliant support providers.
Company Size
51-200
Company Stage
Post IPO Equity
Headquarters
Waltham, Massachusetts
Founded
2024
Get referred to Jade Biosciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- On June 5, 2026, Jade closed a $150 million offering, extending runway into 2028.
- Phase 2 JUNIPER began May 26, 2026, accelerating registrational planning for 2027.
- Mark Eisner joined June 26, 2026, adding Vir, Genentech, and Roche experience.
What critics are saying
- Vera's atacicept won FDA approval July 2026, crowding Jade's IgAN window.
- Otsuka's VOYXACT approved November 2025, setting a selective APRIL benchmark before Jade's Phase 3.
- Jade still depends on JADE101; failure in 2027 likely forces dilution or shutdown.
What makes Jade Biosciences unique
- JADE101 showed femtomolar APRIL binding and 12-week IgA suppression on June 1, 2026.
- Paragon Therapeutics and Fairmount built Jade's pipeline, following Apogee, Spyre, and Oruka.
- JADE201 and JADE301 diversify beyond JADE101, spanning BAFF-R and undisclosed antibodies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 27%1 year growth
↑ 27%2 year growth
↑ 47%Jade Biosciences appoints Dr. Mark Eisner to Board of Directors. June 26, 2026 Dr. Mark Eisner Jade Biosciences (Nasdaq: JBIO) has appointed biopharmaceutical executive Dr. Mark Eisner to its board of directors, effective June 25, 2026, adding a veteran drug development leader as the clinical-stage biotechnology company advances its pipeline of antibody-based therapies for autoimmune diseases. Eisner brings more than 25 years of experience in clinical development, immunology and regulatory strategy, with a track record spanning early-stage research through global product approvals and commercialization. His appointment comes as Jade continues developing multiple antibody candidates targeting autoimmune disorders, including its lead program for immunoglobulin A (IgA) nephropathy. "We are pleased to welcome Dr. Eisner to the board," said Tom Frohlich, chief executive officer of Jade Biosciences. "Mark's biopharmaceutical executive experience and proven track record guiding innovative therapies from early clinical development through regulatory approval and global commercialization will be highly valuable as Jade rapidly advances its pipeline of antibody-based therapies for autoimmune diseases." Most recently, Eisner served as executive vice president and chief medical officer at Vir Biotechnology, where he led the company's clinical development, regulatory sciences and medical affairs organizations. Before that, he held chief medical officer positions at Sonoma Biotherapeutics and FibroGen. Earlier in his career, Eisner spent nearly 11 years at Genentech/Roche, ultimately serving as senior vice president and global head of product development for immunology, infectious disease and ophthalmology. In that role, he directed multinational clinical development programs and global regulatory submissions across several therapeutic areas, providing experience that aligns with Jade's strategy of advancing novel antibody therapies through clinical development. Prior to joining the biotechnology industry, Eisner was a professor of medicine and anesthesia at the University of California, San Francisco. "I am excited to join the Board of Directors at Jade as the Company rapidly advances its portfolio of potential best-in-class therapies for multiple autoimmune diseases," Eisner said. "Jade is well-positioned to address areas of substantial unmet need for patients, and I look forward to contributing as a board member to support the impact." Jade Biosciences is developing therapies for autoimmune diseases where treatment options remain limited. Its lead clinical candidate, JADE101, targets the cytokine APRIL and is currently being evaluated for the treatment of immunoglobulin A nephropathy, a chronic kidney disease driven by abnormal immune system activity. The company's broader pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an undisclosed antibody program. Jade was launched around assets licensed from Paragon Therapeutics, an antibody discovery company founded by Fairmount. By adding Eisner to its board, Jade strengthens its clinical and regulatory expertise as it advances multiple antibody programs through development, with a focus on translating promising immunology research into therapies for patients with autoimmune diseases.
SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the pricing of a public offering of 10,000,000 shares of its common stock. The shares of common stock are being … Continued
Jade Biosciences has priced a public offering of 10 million common shares at $15.00 per share, expecting gross proceeds of $150 million before expenses. Underwriters have a 30-day option to purchase up to an additional 1.5 million shares. The clinical-stage biotechnology company, focused on autoimmune disease therapies, will use net proceeds alongside existing cash to fund clinical trials, preclinical studies, manufacturing, research and development, capital expenditures and working capital. The offering is expected to close on 5 June 2026. Jefferies, TD Cowen and UBS Investment Bank are acting as joint book-running managers, with LifeSci Capital as passive book-running manager and BTIG as lead manager. The shares are being offered pursuant to an effective Form S-3 shelf registration statement.
Jade Biosciences has raised $45 million in a private placement led by BB Biotech, selling 3,214,286 shares of common stock at $14.00 per share. The transaction is expected to close on 16 December 2025, subject to customary closing conditions. The clinical-stage biotechnology company, which focuses on autoimmune disease therapies, will use proceeds to fund research and development, general corporate expenses and working capital. The shares are unregistered, and Jade has agreed to file a registration statement with the SEC to enable resale under a registration rights agreement. This marks Jade's second significant capital raise in recent months, following a $135 million private placement in October 2025. The company is currently developing JADE101, targeting cytokine APRIL for immunoglobulin A nephropathy treatment.
Jade Biosciences Inc. has unveiled JADE-201, a monoclonal antibody.